| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 25 | 2022 | 1058 | 1.650 |
Why?
|
| Carcinoma, Squamous Cell | 19 | 2019 | 1065 | 1.590 |
Why?
|
| Salivary Gland Neoplasms | 5 | 2019 | 65 | 1.370 |
Why?
|
| Carcinoma, Mucoepidermoid | 2 | 2019 | 17 | 1.360 |
Why?
|
| Otolaryngology | 2 | 2023 | 57 | 1.280 |
Why?
|
| Chemoradiotherapy | 14 | 2022 | 305 | 1.060 |
Why?
|
| Neoplasm Recurrence, Local | 13 | 2022 | 1257 | 0.970 |
Why?
|
| Otolaryngologists | 1 | 2023 | 4 | 0.950 |
Why?
|
| Actinomycosis | 1 | 2022 | 12 | 0.910 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 20 | 2022 | 2390 | 0.890 |
Why?
|
| Larynx | 1 | 2022 | 39 | 0.890 |
Why?
|
| Oropharyngeal Neoplasms | 6 | 2022 | 124 | 0.850 |
Why?
|
| Perforator Flap | 1 | 2020 | 12 | 0.770 |
Why?
|
| Paranasal Sinus Diseases | 2 | 2018 | 24 | 0.730 |
Why?
|
| Mouth Neoplasms | 7 | 2018 | 196 | 0.730 |
Why?
|
| Gene Rearrangement | 2 | 2019 | 169 | 0.720 |
Why?
|
| Papillomavirus Infections | 5 | 2022 | 243 | 0.680 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 336 | 0.660 |
Why?
|
| Laryngeal Diseases | 2 | 2015 | 19 | 0.640 |
Why?
|
| Nose Diseases | 1 | 2017 | 10 | 0.640 |
Why?
|
| Nose Neoplasms | 1 | 2017 | 31 | 0.640 |
Why?
|
| Nasal Cavity | 1 | 2017 | 91 | 0.610 |
Why?
|
| Maxillary Sinus | 2 | 2018 | 26 | 0.610 |
Why?
|
| Trans-Activators | 1 | 2019 | 428 | 0.590 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2016 | 24 | 0.570 |
Why?
|
| Aspergillosis | 1 | 2016 | 40 | 0.560 |
Why?
|
| Cementoma | 1 | 2015 | 2 | 0.560 |
Why?
|
| Mandibular Neoplasms | 1 | 2015 | 24 | 0.540 |
Why?
|
| Sarcoidosis | 1 | 2015 | 67 | 0.530 |
Why?
|
| Papillomaviridae | 4 | 2022 | 155 | 0.510 |
Why?
|
| Laryngeal Neoplasms | 5 | 2017 | 89 | 0.500 |
Why?
|
| Female | 53 | 2023 | 43741 | 0.470 |
Why?
|
| Humans | 72 | 2023 | 83872 | 0.470 |
Why?
|
| Sjogren's Syndrome | 3 | 2009 | 29 | 0.470 |
Why?
|
| Salivary Glands, Minor | 2 | 2009 | 9 | 0.460 |
Why?
|
| Middle Aged | 43 | 2022 | 24690 | 0.460 |
Why?
|
| Aged, 80 and over | 21 | 2020 | 6453 | 0.440 |
Why?
|
| Biomarkers, Tumor | 2 | 2022 | 1440 | 0.430 |
Why?
|
| Male | 50 | 2023 | 40238 | 0.420 |
Why?
|
| Adult | 40 | 2023 | 25203 | 0.410 |
Why?
|
| Airway Management | 1 | 2012 | 45 | 0.410 |
Why?
|
| Carcinoma | 3 | 2022 | 427 | 0.380 |
Why?
|
| Placenta | 1 | 2011 | 169 | 0.380 |
Why?
|
| Aged | 34 | 2020 | 18097 | 0.370 |
Why?
|
| Anesthesiology | 1 | 2012 | 152 | 0.370 |
Why?
|
| Quinazolines | 4 | 2012 | 217 | 0.360 |
Why?
|
| Hydroxyurea | 10 | 2022 | 239 | 0.360 |
Why?
|
| Leukoplakia, Oral | 2 | 2023 | 10 | 0.360 |
Why?
|
| Induction Chemotherapy | 6 | 2022 | 147 | 0.350 |
Why?
|
| Disease-Free Survival | 15 | 2020 | 1203 | 0.330 |
Why?
|
| Fluorouracil | 10 | 2022 | 549 | 0.320 |
Why?
|
| Neck | 2 | 2020 | 98 | 0.310 |
Why?
|
| Head | 2 | 2020 | 130 | 0.310 |
Why?
|
| Radiotherapy, Intensity-Modulated | 5 | 2016 | 182 | 0.300 |
Why?
|
| Clinical Competence | 1 | 2012 | 746 | 0.290 |
Why?
|
| Anti-Bacterial Agents | 3 | 2022 | 702 | 0.280 |
Why?
|
| Radiotherapy Dosage | 11 | 2020 | 488 | 0.280 |
Why?
|
| Warts | 2 | 2019 | 11 | 0.270 |
Why?
|
| Paclitaxel | 6 | 2022 | 458 | 0.270 |
Why?
|
| Tongue Neoplasms | 4 | 2018 | 52 | 0.260 |
Why?
|
| ErbB Receptors | 4 | 2016 | 480 | 0.260 |
Why?
|
| Diagnosis, Differential | 4 | 2017 | 1535 | 0.260 |
Why?
|
| Nasopharyngeal Neoplasms | 2 | 2016 | 46 | 0.260 |
Why?
|
| Treatment Outcome | 17 | 2022 | 7776 | 0.240 |
Why?
|
| Antineoplastic Agents | 6 | 2012 | 2324 | 0.240 |
Why?
|
| Oral and Maxillofacial Surgeons | 1 | 2023 | 4 | 0.240 |
Why?
|
| Alphapapillomavirus | 2 | 2021 | 48 | 0.240 |
Why?
|
| Irritants | 1 | 2022 | 4 | 0.230 |
Why?
|
| Pharynx | 1 | 2022 | 46 | 0.230 |
Why?
|
| Neoplasm Staging | 12 | 2016 | 1931 | 0.230 |
Why?
|
| Re-Irradiation | 1 | 2022 | 16 | 0.220 |
Why?
|
| HIV-1 | 1 | 2023 | 140 | 0.220 |
Why?
|
| Laryngostenosis | 1 | 2021 | 16 | 0.210 |
Why?
|
| Tracheal Stenosis | 1 | 2021 | 23 | 0.210 |
Why?
|
| Drug Monitoring | 1 | 2022 | 117 | 0.200 |
Why?
|
| DNA, Viral | 1 | 2022 | 263 | 0.200 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 2020 | 13 | 0.200 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 60 | 0.200 |
Why?
|
| Respiratory System | 1 | 2021 | 116 | 0.200 |
Why?
|
| Anti-HIV Agents | 1 | 2023 | 139 | 0.200 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2019 | 348 | 0.200 |
Why?
|
| Follow-Up Studies | 13 | 2019 | 3603 | 0.190 |
Why?
|
| ras Proteins | 1 | 2020 | 128 | 0.190 |
Why?
|
| United States | 7 | 2023 | 6425 | 0.190 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2020 | 136 | 0.190 |
Why?
|
| Lymph Nodes | 2 | 2016 | 527 | 0.190 |
Why?
|
| Risk Factors | 8 | 2019 | 5301 | 0.180 |
Why?
|
| Smoking | 3 | 2014 | 600 | 0.180 |
Why?
|
| Cetuximab | 2 | 2019 | 114 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 1033 | 0.180 |
Why?
|
| Young Adult | 6 | 2022 | 5843 | 0.180 |
Why?
|
| Thyroid Neoplasms | 2 | 2020 | 400 | 0.180 |
Why?
|
| Prognosis | 9 | 2022 | 3617 | 0.180 |
Why?
|
| Arteries | 1 | 2020 | 169 | 0.180 |
Why?
|
| Radiation Dosage | 1 | 2020 | 223 | 0.180 |
Why?
|
| Retrospective Studies | 15 | 2018 | 8061 | 0.180 |
Why?
|
| Heterocyclic Compounds | 1 | 2019 | 17 | 0.180 |
Why?
|
| Maximum Tolerated Dose | 4 | 2022 | 270 | 0.180 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2019 | 47 | 0.180 |
Why?
|
| Combined Modality Therapy | 9 | 2016 | 1645 | 0.170 |
Why?
|
| Receptors, CXCR4 | 1 | 2019 | 41 | 0.170 |
Why?
|
| Bone Cysts, Aneurysmal | 1 | 2018 | 7 | 0.170 |
Why?
|
| Lip | 2 | 2009 | 16 | 0.170 |
Why?
|
| Precancerous Conditions | 2 | 2016 | 194 | 0.170 |
Why?
|
| Carboplatin | 4 | 2022 | 286 | 0.170 |
Why?
|
| Deglutition | 3 | 2020 | 68 | 0.170 |
Why?
|
| Dental Alloys | 1 | 2018 | 6 | 0.170 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2018 | 57 | 0.170 |
Why?
|
| Orthodontic Appliances | 1 | 2018 | 8 | 0.170 |
Why?
|
| Erlotinib Hydrochloride | 2 | 2016 | 90 | 0.160 |
Why?
|
| Inflammation | 2 | 2017 | 875 | 0.160 |
Why?
|
| Child | 6 | 2019 | 6706 | 0.160 |
Why?
|
| Adolescent | 7 | 2022 | 8806 | 0.160 |
Why?
|
| Glottis | 1 | 2017 | 12 | 0.160 |
Why?
|
| Mammary Analogue Secretory Carcinoma | 1 | 2017 | 4 | 0.160 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 2414 | 0.160 |
Why?
|
| Bone Marrow | 1 | 2019 | 430 | 0.150 |
Why?
|
| Life Style | 1 | 2018 | 184 | 0.150 |
Why?
|
| Hypopharyngeal Neoplasms | 2 | 2011 | 15 | 0.150 |
Why?
|
| Prospective Studies | 7 | 2022 | 4090 | 0.150 |
Why?
|
| Fibrosis | 1 | 2017 | 194 | 0.150 |
Why?
|
| Transcriptome | 1 | 2020 | 546 | 0.150 |
Why?
|
| Professionalism | 1 | 2016 | 24 | 0.140 |
Why?
|
| Time Factors | 4 | 2019 | 5176 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 3 | 2016 | 522 | 0.140 |
Why?
|
| Fibroma, Ossifying | 1 | 2015 | 5 | 0.140 |
Why?
|
| Anticarcinogenic Agents | 1 | 2016 | 70 | 0.140 |
Why?
|
| Guideline Adherence | 1 | 2017 | 224 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 1181 | 0.140 |
Why?
|
| Premedication | 1 | 1995 | 54 | 0.140 |
Why?
|
| Pleural Neoplasms | 1 | 2017 | 184 | 0.140 |
Why?
|
| Simulation Training | 1 | 2016 | 88 | 0.130 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1636 | 0.130 |
Why?
|
| HIV Infections | 1 | 2023 | 725 | 0.130 |
Why?
|
| Cerebellopontine Angle | 1 | 1994 | 7 | 0.130 |
Why?
|
| Ulnar Nerve | 1 | 1994 | 6 | 0.130 |
Why?
|
| Neuroma, Acoustic | 1 | 1994 | 20 | 0.130 |
Why?
|
| Tumor Virus Infections | 1 | 2014 | 81 | 0.130 |
Why?
|
| Neuromuscular Blocking Agents | 1 | 1994 | 28 | 0.120 |
Why?
|
| Facial Nerve | 1 | 1994 | 33 | 0.120 |
Why?
|
| Aminolevulinic Acid | 1 | 2013 | 21 | 0.120 |
Why?
|
| Photosensitizing Agents | 1 | 2013 | 47 | 0.120 |
Why?
|
| Biopsy | 4 | 2009 | 1139 | 0.120 |
Why?
|
| Monitoring, Intraoperative | 1 | 1994 | 107 | 0.120 |
Why?
|
| Mouth | 2 | 2011 | 48 | 0.120 |
Why?
|
| Photochemotherapy | 1 | 2013 | 95 | 0.110 |
Why?
|
| Pain | 1 | 2015 | 383 | 0.110 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2012 | 96 | 0.110 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 358 | 0.110 |
Why?
|
| Radiotherapy | 2 | 2011 | 326 | 0.110 |
Why?
|
| Survival Analysis | 5 | 2018 | 1531 | 0.110 |
Why?
|
| Lymph Node Excision | 1 | 2013 | 208 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 586 | 0.100 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2011 | 35 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2012 | 461 | 0.100 |
Why?
|
| Deglutition Disorders | 2 | 2011 | 105 | 0.100 |
Why?
|
| Research Design | 2 | 2013 | 581 | 0.100 |
Why?
|
| Tracheotomy | 1 | 2011 | 18 | 0.100 |
Why?
|
| Organ Preservation | 1 | 2011 | 75 | 0.100 |
Why?
|
| Survival Rate | 4 | 2019 | 1843 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 2231 | 0.100 |
Why?
|
| Speech | 1 | 2010 | 82 | 0.100 |
Why?
|
| Brain Diseases | 1 | 2011 | 177 | 0.100 |
Why?
|
| Agammaglobulinemia | 1 | 2010 | 20 | 0.090 |
Why?
|
| Airway Obstruction | 1 | 2011 | 108 | 0.090 |
Why?
|
| Vocal Cords | 1 | 2009 | 23 | 0.090 |
Why?
|
| Developmental Disabilities | 1 | 2011 | 192 | 0.090 |
Why?
|
| Quality of Life | 3 | 2012 | 1504 | 0.090 |
Why?
|
| Emergency Medical Services | 1 | 2012 | 195 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2013 | 854 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2009 | 387 | 0.090 |
Why?
|
| Cohort Studies | 5 | 2018 | 2703 | 0.090 |
Why?
|
| Genomics | 1 | 2014 | 678 | 0.090 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2008 | 49 | 0.090 |
Why?
|
| Confidence Intervals | 4 | 2018 | 227 | 0.090 |
Why?
|
| Neck Dissection | 4 | 2010 | 67 | 0.090 |
Why?
|
| Enteral Nutrition | 2 | 2020 | 103 | 0.090 |
Why?
|
| Myelitis, Transverse | 1 | 2008 | 10 | 0.090 |
Why?
|
| Submandibular Gland Diseases | 1 | 2008 | 9 | 0.090 |
Why?
|
| Neoplasms, Second Primary | 1 | 2011 | 250 | 0.090 |
Why?
|
| Skin | 1 | 2012 | 550 | 0.090 |
Why?
|
| Military Personnel | 1 | 2009 | 79 | 0.090 |
Why?
|
| Neuromyelitis Optica | 1 | 2008 | 21 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 2 | 2012 | 308 | 0.080 |
Why?
|
| Aortic Aneurysm | 1 | 1988 | 79 | 0.080 |
Why?
|
| Risk Assessment | 5 | 2016 | 2223 | 0.080 |
Why?
|
| Fatal Outcome | 2 | 2019 | 290 | 0.080 |
Why?
|
| Taxoids | 1 | 2007 | 129 | 0.080 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2006 | 13 | 0.080 |
Why?
|
| DNA | 1 | 2012 | 1271 | 0.080 |
Why?
|
| Tinnitus | 1 | 2006 | 21 | 0.070 |
Why?
|
| Incidence | 3 | 2018 | 1565 | 0.070 |
Why?
|
| Headache | 1 | 2006 | 69 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 2 | 2010 | 1357 | 0.070 |
Why?
|
| Prodrugs | 2 | 1996 | 44 | 0.070 |
Why?
|
| Drug Administration Schedule | 4 | 2016 | 917 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 1948 | 0.070 |
Why?
|
| Infant, Newborn | 1 | 2011 | 2322 | 0.070 |
Why?
|
| Drug Therapy, Combination | 3 | 1999 | 883 | 0.070 |
Why?
|
| Cisplatin | 2 | 2022 | 600 | 0.070 |
Why?
|
| Bevacizumab | 3 | 2011 | 276 | 0.070 |
Why?
|
| Pregnancy | 1 | 2011 | 2795 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2011 | 1155 | 0.060 |
Why?
|
| Gastroesophageal Reflux | 2 | 2009 | 113 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2017 | 104 | 0.060 |
Why?
|
| Lamivudine | 1 | 2023 | 12 | 0.060 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2023 | 24 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2010 | 291 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2011 | 2497 | 0.060 |
Why?
|
| Internship and Residency | 1 | 2012 | 977 | 0.060 |
Why?
|
| Remission Induction | 2 | 2016 | 709 | 0.060 |
Why?
|
| Immunohistochemistry | 3 | 2017 | 1736 | 0.060 |
Why?
|
| Alcohol Drinking | 2 | 2018 | 263 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2020 | 1355 | 0.050 |
Why?
|
| Retreatment | 2 | 2012 | 107 | 0.050 |
Why?
|
| Albumins | 1 | 2022 | 135 | 0.050 |
Why?
|
| Pulmonary Surgical Procedures | 1 | 2021 | 8 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2023 | 324 | 0.050 |
Why?
|
| Receptor, Endothelin A | 1 | 2021 | 22 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2013 | 173 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2021 | 133 | 0.050 |
Why?
|
| Endothelial Growth Factors | 1 | 2001 | 55 | 0.050 |
Why?
|
| Lymphokines | 1 | 2001 | 75 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2021 | 205 | 0.050 |
Why?
|
| Periodontal Diseases | 1 | 2000 | 9 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2011 | 918 | 0.050 |
Why?
|
| Radiography | 2 | 2014 | 799 | 0.050 |
Why?
|
| Lymphoid Tissue | 1 | 2000 | 57 | 0.050 |
Why?
|
| Bronchoscopy | 1 | 2021 | 144 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2000 | 146 | 0.050 |
Why?
|
| Disease Progression | 2 | 2017 | 1478 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2022 | 741 | 0.050 |
Why?
|
| Carcinoma, Papillary | 1 | 2001 | 158 | 0.050 |
Why?
|
| Clindamycin | 2 | 1999 | 13 | 0.050 |
Why?
|
| Cefuroxime | 2 | 1996 | 3 | 0.050 |
Why?
|
| Tonsillectomy | 1 | 1999 | 29 | 0.050 |
Why?
|
| Benzylamines | 1 | 2019 | 16 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2021 | 197 | 0.040 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2019 | 19 | 0.040 |
Why?
|
| Aortic Rupture | 2 | 1990 | 53 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2021 | 274 | 0.040 |
Why?
|
| Bone Marrow Examination | 1 | 2019 | 48 | 0.040 |
Why?
|
| Antibiotic Prophylaxis | 1 | 1999 | 72 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 422 | 0.040 |
Why?
|
| Primary Myelofibrosis | 1 | 2019 | 56 | 0.040 |
Why?
|
| Oral Health | 1 | 2018 | 11 | 0.040 |
Why?
|
| Double-Blind Method | 3 | 2016 | 1797 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2017 | 11 | 0.040 |
Why?
|
| Myoepithelioma | 1 | 2017 | 11 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2017 | 24 | 0.040 |
Why?
|
| Metals | 1 | 2018 | 89 | 0.040 |
Why?
|
| Laryngectomy | 1 | 2017 | 26 | 0.040 |
Why?
|
| Surgical Wound Infection | 2 | 1999 | 185 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2011 | 988 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2009 | 305 | 0.040 |
Why?
|
| Parotid Gland | 1 | 2017 | 31 | 0.040 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2017 | 62 | 0.040 |
Why?
|
| Mutation | 2 | 2020 | 3889 | 0.040 |
Why?
|
| Biomarkers | 1 | 2023 | 1654 | 0.040 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2017 | 129 | 0.040 |
Why?
|
| Probability | 2 | 2008 | 351 | 0.040 |
Why?
|
| Otitis Media | 1 | 1996 | 16 | 0.040 |
Why?
|
| Translocation, Genetic | 1 | 2017 | 265 | 0.040 |
Why?
|
| Everolimus | 1 | 2016 | 40 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2017 | 152 | 0.040 |
Why?
|
| Loss of Heterozygosity | 1 | 2016 | 85 | 0.040 |
Why?
|
| Otitis Media with Effusion | 1 | 1995 | 6 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 397 | 0.040 |
Why?
|
| Cutaneous Fistula | 1 | 1995 | 13 | 0.030 |
Why?
|
| Cellulitis | 1 | 1995 | 19 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 3253 | 0.030 |
Why?
|
| Cephalosporins | 1 | 1995 | 22 | 0.030 |
Why?
|
| Pyridines | 1 | 2017 | 305 | 0.030 |
Why?
|
| Dissection | 1 | 1995 | 42 | 0.030 |
Why?
|
| Human papillomavirus 18 | 1 | 2014 | 16 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 1995 | 150 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 1038 | 0.030 |
Why?
|
| Human papillomavirus 16 | 1 | 2014 | 38 | 0.030 |
Why?
|
| Drug Costs | 1 | 1995 | 61 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2014 | 49 | 0.030 |
Why?
|
| Hospital Costs | 1 | 1995 | 100 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 685 | 0.030 |
Why?
|
| Electromyography | 1 | 1994 | 183 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2017 | 573 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 580 | 0.030 |
Why?
|
| Clavulanic Acids | 3 | 1999 | 3 | 0.030 |
Why?
|
| Amoxicillin-Potassium Clavulanate Combination | 3 | 1999 | 4 | 0.030 |
Why?
|
| Amoxicillin | 3 | 1999 | 13 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 171 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2013 | 145 | 0.030 |
Why?
|
| Electric Stimulation | 1 | 1994 | 340 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 1823 | 0.030 |
Why?
|
| Rabbits | 1 | 1994 | 634 | 0.030 |
Why?
|
| Platinum | 1 | 2012 | 61 | 0.030 |
Why?
|
| Phenotype | 1 | 2019 | 2323 | 0.030 |
Why?
|
| Aorta, Abdominal | 2 | 1990 | 59 | 0.030 |
Why?
|
| Organ Sparing Treatments | 1 | 2011 | 35 | 0.030 |
Why?
|
| Length of Stay | 1 | 1995 | 684 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 573 | 0.030 |
Why?
|
| Supraglottitis | 1 | 2011 | 3 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2012 | 192 | 0.030 |
Why?
|
| Pemetrexed | 1 | 2011 | 76 | 0.030 |
Why?
|
| Glutamates | 1 | 2011 | 89 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2012 | 236 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2011 | 150 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2012 | 340 | 0.020 |
Why?
|
| Leucovorin | 1 | 2010 | 219 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2012 | 276 | 0.020 |
Why?
|
| Osteoradionecrosis | 1 | 2010 | 17 | 0.020 |
Why?
|
| Guanine | 1 | 2011 | 206 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 2010 | 232 | 0.020 |
Why?
|
| Camptothecin | 1 | 2010 | 189 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2011 | 236 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2010 | 305 | 0.020 |
Why?
|
| Laryngoscopy | 1 | 2009 | 45 | 0.020 |
Why?
|
| Siblings | 1 | 2010 | 110 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 284 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2009 | 189 | 0.020 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2009 | 48 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 1999 | 2195 | 0.020 |
Why?
|
| Syndrome | 1 | 2010 | 432 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 357 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2009 | 77 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2010 | 247 | 0.020 |
Why?
|
| Arteriosclerosis | 1 | 1988 | 111 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 1008 | 0.020 |
Why?
|
| Hypersensitivity | 1 | 2009 | 144 | 0.020 |
Why?
|
| Bacterial Infections | 1 | 2010 | 179 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2009 | 479 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 1049 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2009 | 596 | 0.020 |
Why?
|
| Autoantibodies | 1 | 2008 | 257 | 0.020 |
Why?
|
| Cranial Sinuses | 1 | 2006 | 14 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2008 | 670 | 0.020 |
Why?
|
| Blood Vessel Prosthesis | 1 | 1988 | 221 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 533 | 0.020 |
Why?
|
| Comorbidity | 1 | 2009 | 933 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 1988 | 429 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 1 | 2006 | 207 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 1988 | 333 | 0.020 |
Why?
|
| Prevalence | 1 | 2008 | 1218 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2014 | 3179 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2006 | 393 | 0.010 |
Why?
|
| Algorithms | 1 | 2011 | 1803 | 0.010 |
Why?
|
| Registries | 1 | 2006 | 687 | 0.010 |
Why?
|
| Asthma | 1 | 2009 | 929 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2001 | 57 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2006 | 1786 | 0.010 |
Why?
|
| Ticarcillin | 1 | 1999 | 1 | 0.010 |
Why?
|
| Mouthwashes | 1 | 1999 | 5 | 0.010 |
Why?
|
| Ampicillin | 1 | 1999 | 15 | 0.010 |
Why?
|
| Administration, Topical | 1 | 1999 | 91 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1999 | 241 | 0.010 |
Why?
|
| Infant | 2 | 1996 | 2993 | 0.010 |
Why?
|
| Child, Preschool | 2 | 1996 | 3569 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1999 | 816 | 0.010 |
Why?
|
| Animals | 2 | 1994 | 26005 | 0.010 |
Why?
|
| Suspensions | 1 | 1996 | 6 | 0.010 |
Why?
|
| Bacteria | 1 | 1999 | 432 | 0.010 |
Why?
|
| Acute Disease | 1 | 1996 | 811 | 0.010 |
Why?
|
| Back Pain | 1 | 1990 | 36 | 0.010 |
Why?
|
| Hematoma | 1 | 1990 | 95 | 0.010 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 1988 | 5 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1988 | 132 | 0.010 |
Why?
|
| Polytetrafluoroethylene | 1 | 1988 | 73 | 0.010 |
Why?
|
| Jugular Veins | 1 | 1988 | 70 | 0.010 |
Why?
|
| Microcirculation | 1 | 1988 | 103 | 0.010 |
Why?
|
| Omentum | 1 | 1988 | 71 | 0.010 |
Why?
|
| Dogs | 1 | 1988 | 680 | 0.000 |
Why?
|
| Aorta | 1 | 1988 | 274 | 0.000 |
Why?
|
| Thrombosis | 1 | 1988 | 284 | 0.000 |
Why?
|